Clinical Pharmacology Operational Expert Group
Submitted by Anonymous (not verified) on 16 February 2026 - 16:21
Clinical Pharmacology Operational Expert Group
Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 7, Status: Authorised
Submitted by Anonymous (not verified) on 16 February 2026 - 15:49
Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 7, Status: Authorised
PSUSA/00010606/202506
Submitted by Anonymous (not verified) on 16 February 2026 - 15:02
PSUSA/00010606/202506
Human medicines European public assessment report (EPAR): Pregabalin Zentiva, pregabalin, Date of authorisation: 17/07/2015, Revision: 19, Status: Authorised
Submitted by Anonymous (not verified) on 16 February 2026 - 14:40
Human medicines European public assessment report (EPAR): Pregabalin Zentiva, pregabalin, Date of authorisation: 17/07/2015, Revision: 19, Status: Authorised
Committee for Orphan Medicinal Products (COMP): 17-19 February 2026, European Medicines Agency, Amsterdam, the Netherlands, from 17 February 2026 to 19 February 2026
Submitted by Anonymous (not verified) on 16 February 2026 - 14:38
Committee for Orphan Medicinal Products (COMP): 17-19 February 2026, European Medicines Agency, Amsterdam, the Netherlands, from 17 February 2026 to 19 February 2026
Human medicines European public assessment report (EPAR): Orphacol, cholic acid, Date of authorisation: 12/09/2013, Revision: 16, Status: Authorised
Submitted by Anonymous (not verified) on 16 February 2026 - 13:55
Human medicines European public assessment report (EPAR): Orphacol, cholic acid, Date of authorisation: 12/09/2013, Revision: 16, Status: Authorised
Human medicines European public assessment report (EPAR): Dovato, dolutegravir,lamivudine, Date of authorisation: 01/07/2019, Revision: 20, Status: Authorised
Submitted by Anonymous (not verified) on 16 February 2026 - 13:42
Human medicines European public assessment report (EPAR): Dovato, dolutegravir,lamivudine, Date of authorisation: 01/07/2019, Revision: 20, Status: Authorised
GLP-1 Receptor Agonists: Applications in Clinical Practice
Submitted by Catalina on 16 February 2026 - 13:17
The EFIM Young Internists and Austrian Young Internists are pleased to invite you to their upcoming webinar "GLP-1 Receptor Agonists: Applications in Clinical Practice", taking place on Wednesday, February 18th, at 19:00 CET.
Moderated by Dr. Noor Lasheen and Dr. Jakub Jurica.
Join us for this insightful session and engage with the expert speaker Dr. Adrian Szodl.
Registration details available in the link below:
PSUSA/00010572/202506
Submitted by Anonymous (not verified) on 16 February 2026 - 13:16
PSUSA/00010572/202506
Human medicines European public assessment report (EPAR): Luxturna, voretigene neparvovec, Date of authorisation: 22/11/2018, Revision: 12, Status: Authorised
Submitted by Anonymous (not verified) on 16 February 2026 - 13:15
Human medicines European public assessment report (EPAR): Luxturna, voretigene neparvovec, Date of authorisation: 22/11/2018, Revision: 12, Status: Authorised